The Working Group concluded the evidence did not conclusively show that screening with the PSA test reduced prostate cancer mortality, whereas evidence suggested an increased risk of harm in individuals younger than 55 years of age or older than 70 years of age. This evidence concerns the gene KLK3 and prostate carcinoma.